Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 95 (intetumumab) plus docetaxel in metastatic hormone refractory prostate cancer
DRKS00003882Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Intetumumab + docetaxel + prednisone with Placebo + docetaxel + prednisone (2 arms). Started Apr 2012; status: completed.
02
Drugs
intetumumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on DRKS00003882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003882.